+1-626-295-2442 (Worldwide) 400-606-8865 (China)
Sign in Register
English

Global Human Rabies Immunoglobulin (IM) Market is Projected to Reach USD 513 million by 2024

Author: QYResearch | Publish date: 2018-05-30 | Views: 46
The Human Rabies Immunoglobulin (IM) industry was 286 million USD in 2017 and is projected to reach USD 513 million USD by 2024, at a CAGR (Compounded Annual Growth Rate) of 5.36% between 2017 and 2024. The market is driven by various end-user industries, such as Category II Exposure, Category III Exposure.

The industry is concentration, the key brand include CSL Behring, Grifols , Sanofi, Sichuan Yuanda Shuyang, CNBG, Kamada, CBPO, Shuanglin Bio, Weiguang Bio, Shanghai RAAS, Bharat Serum, VINSand so on. Among them, CSL Behring and CNBG are the leaders.


The leading companies own the advantages on better performance, more abundant product’s types, better technical and impeccable after-sales service. Consequently, they take the majority of the market share of high-end market. Looking to the future years, the slow downward price trend in recent years will maintain. As competition intensifies, prices gap between different brands will go narrowing. Similarly, there will be fluctuation in gross margin.


Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure. It is given after the wound is cleaned with soap and water or providone-iodine and is followed by a course of rabies vaccine.

 

The use of rabies immunoglobulin in the form of blood serum dates from 1891. Use become common within medicine in the 1950s. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.


The industry is expected to remain innovation-led, with frequent acquisitions and strategic alliances adopted as the key strategies by the players to increase their industry presence. Market stays in mature period with a clear concentration. Meanwhile, optimize product mix and further develop value-added capabilities to maximize margins.


The Global Human Rabies Immunoglobulin (IM) Market Research Report 2017 report released by QYResearch provides a basic overview of the Human Rabies Immunoglobulin (IM) industry, including definition, classification, application and industrial chain structure. Discuss development policies and plans as well as manufacturing processes and cost structures.


The report then focuses on major industry players in Global, including company profiles, product images and specifications, sales, market share, and contact information. More importantly, the Human Rabies Immunoglobulin (IM) industry development trends and marketing channels were analyzed. Providing the main statistical data on the current status of the industry is a valuable guide and direction for companies and individuals interested in the market.


CONTACT US
We will be happy to help you find what you're looking for. Please call or email us
  • USA Office: +1-6262952442(International) ; +1-6265407211
  • Canada Office: +1-6133665094
Our clients
<
4321
>
>